

## **Product datasheet for TL301538**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **SLC7A14 Human shRNA Plasmid Kit (Locus ID 57709)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** SLC7A14 Human shRNA Plasmid Kit (Locus ID 57709)

**Locus ID:** 57709

Synonyms: PPP1R142

**Vector:** pGFP-C-shLenti (TR30023)

**E. coli Selection:** Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

Components: SLC7A14 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID =

57709). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 020949, NM 020949.1, NM 020949.2, BC022968

UniProt ID: Q8TBB6


**Summary:** This gene is predicted to encode a glycosylated, cationic amino acid transporter protein with

14 transmembrane domains. This gene is primarily expressed in skin fibroblasts, neural tissue, and primary endothelial cells and its protein is predicted to mediate lysosomal uptake of cationic amino acids. Mutations in this gene are associated with autosomal recessive retinitis pigmentosa. In mice, this gene is expressed in the photoreceptor layer of the retina where its expression increases over the course of retinal development and persists in the

mature retina. [provided by RefSeq, Apr 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).